Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions

From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.

• Source: Shutterstock

Approval of OTC switches in the US has continued since the Food and Drug Administration in 2012 announced its interest in making drugs available nonprescription for chronic conditions currently limited to Rx drug indications.

More from Rx-to-OTC Switch

More from Health